| Role of NO and angiotensin II in the early development of endothelial functions impairment and cardiac hypertrophy in deoxycorticosterone acetate-salt hypertension. | |
| | |
MedLine Citation:
|
PMID: 9923405 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This study was designed to investigate the effects of chronic inhibition of NO synthesis as well as chronic angiotensin receptor blockade with losartan in the development of hypertension, on mesenteric arterial bed reactivity as well as on the development of cardiac and kidney hypertrophy in deoxycorticosterone-salt (DOCA) hypertension. Uninephrectomized rats were divided in four experimental groups all receiving saline water to drink and treated or not with losartan over a period of 9 days. Two of these groups were administered DOCA, one of which received also N(G)-nitro-L-arginine-methyl ester (L-NAME) to drink. A third group received only L-NAME, while another group received only saline. Systolic blood pressure was similarly increased in L-NAME, DOCA, DOCA-L-NAME groups. Cardiac and kidney weights were increased in DOCA but significantly reduced in DOCA-L-NAME. Losartan prevented the development of hypertension in all groups and also prevented cardiac and kidney hypertrophy in DOCA. The hyperreactivity of mesenteric arteries to phenylephrine, measured in the presence of indomethacin, was endothelium-dependent in both L-NAME groups but not in DOCA rats. Pretreatment with BQ 123 did not modify these endothelium-dependent responses in L-NAME rats. Chronic losartan prevented endothelium-dependent phenylephrine hyperreactivity only in DOCA, whereas only the removal of the endothelium attenuated the responsiveness in both L-NAME-treated groups. Vasorelaxations to acetylcholine and isoproterenol were attenuated in the three hypertensive groups and were normalized only in DOCA and L-NAME treated with losartan. In summary, in all hypertensive groups, blood pressure was normalized by losartan independently of its effects on endothelial functions. In DOCA, losartan normalized the phenylephrine hyperreactivity through an endothelial-dependent mechanism. However, in L-NAME-treated groups an endothelial-derived contracting factor, other than angiotensin II, endothelin, or vasoconstrictor prostanoids, appears to be activated. Both NO and angiotensin II seem to play a role in the early development of hypertension and organ hypertrophy in DOCA hypertension. |
| | |
Authors:
|
A K-Laflamme; L Oster; R Cardinal; J de Champlain |
Related Documents
:
|
16411165 - Effect of dose rate and mixtures of fungicides on selection for qoi resistance in popul... 9280205 - Psychophysiological reactivity of salt-sensitive normotensive subjects. 1592485 - Interferon gamma attenuates hypertensive renal injury in salt-sensitive dahl rats. 22713705 - Utility of impedance cardiography for the detection of hemodynamic changes in stable pa... 1147025 - Effect of hypoxia on vascular responses to the carotid baroreflex. 9683455 - Simultaneous lv and rv volumes by conductance catheter: effects of lung insufflation on... |
Publication Detail:
|
Type: In Vitro; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Canadian journal of physiology and pharmacology Volume: 76 ISSN: 0008-4212 ISO Abbreviation: Can. J. Physiol. Pharmacol. Publication Date: 1998 Jun |
Date Detail:
|
Created Date: 1999-04-13 Completed Date: 1999-04-13 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0372712 Medline TA: Can J Physiol Pharmacol Country: CANADA |
Other Details:
|
Languages: eng Pagination: 665-75 Citation Subset: IM |
Affiliation:
|
Department of physiology, Faculty of Medicine, Université de Montréal, QC, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin II
/
physiology* Animals Antihypertensive Agents / pharmacology Cardiomegaly / etiology, physiopathology* Desoxycorticosterone Endothelium, Vascular / physiopathology* Hypertension / chemically induced, complications, physiopathology* Losartan / pharmacology Male NG-Nitroarginine Methyl Ester / pharmacology Nitric Oxide / physiology* Nitric Oxide Synthase / antagonists & inhibitors Nitric Oxide Synthase Type III Organ Size / drug effects Rats Rats, Sprague-Dawley Sodium Chloride Splanchnic Circulation / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 10102-43-9/Nitric Oxide; 11128-99-7/Angiotensin II; 114798-26-4/Losartan; 50903-99-6/NG-Nitroarginine Methyl Ester; 64-85-7/Desoxycorticosterone; 7647-14-5/Sodium Chloride; EC 1.14.13.39/Nitric Oxide Synthase; EC 1.14.13.39/Nitric Oxide Synthase Type III; EC 1.14.13.39/Nos3 protein, rat |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Novel attributes of an androgenic steroid-mediated increase in cardiac end diastolic stiffness in ra...
Next Document: Effects of alpha1-antagonists on production and release of aldosterone and other steroid hormones by...